Clinical Trial Update: Clinical Study on the Treatment of MIBC Patients With SHR-A2102 Injection Combined With Adebrelimab (SHR-1316) [Phase 2, Phase 3]

View source ↗

Summary

This clinical trial update indicates SHR-A2102 in combination with Adebrelimab (SHR-1316) is being studied for muscle-invasive bladder cancer in Phase 2 and Pha…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Muscle-invasive Bladder Cancer

Drugs mentioned

• Adebrelimab (adebrelimab)
• SHR-A2102

Snippet

Sponsor: Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Conditions: Muscular Invasive Bladder Cancer (MIBC) | Phase 2, Phase 3 | Status: RECRUITING